期刊
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 26, 期 8, 页码 1229-1237出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1440-1746.2011.06762.x
关键词
cancer stem cells; chemoresistance; hepatocellular carcinoma; liver cancer; miRNA; self-renewal; tumor-initiating cells
资金
- Cancer Genetics, Research Grant Council [HKU1/06C, HKU7/CRG/09, HKU5/CRF/08]
- National Key Sci-Tech Special Project of Infectious Diseases [2008ZX1002-022]
- The University of Hong Kong Strategic Research Theme in Cancer
Hepatocellular carcinoma (HCC) is the most commonly diagnosed malignancy of the liver and is the third most frequent cause of cancer death worldwide. Although advances in HCC detection and treatment have increased the likelihood of a cure at early stages of the disease, HCC remains largely incurable because of late presentation and tumor recurrence. Only 25% of HCC patients are deemed suitable for curative treatment, with the overall survival at just a few months for inoperable patients. Additionally, this disease is particularly difficult to treat because of the high recurrence rate, its chemotherapy-resistant nature and the premalignant nature of surrounding cirrhotic liver disease. In the past few years, compelling evidence has emerged in support of the hierarchic cancer stem cell (CSC)/tumor-initiating cell (T-IC) model for solid tumors, including HCC. Understanding the characteristics and function of CSCs in the liver has also shed light on HCC management and treatment, including the implications for prognosis, prediction and treatment resistance. In this review, a detailed summary of the recent progress in liver CSC research with regard to identification, regulation and therapeutic implications will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据